DVAX
Price
$10.90
Change
+$0.09 (+0.83%)
Updated
Jul 10 closing price
Capitalization
1.62B
20 days until earnings call
TAK
Price
$14.84
Change
-$0.29 (-1.92%)
Updated
Jul 10 closing price
Capitalization
43.11B
19 days until earnings call
Interact to see
Advertisement

DVAX vs TAK

Header iconDVAX vs TAK Comparison
Open Charts DVAX vs TAKBanner chart's image
Dynavax Technologies
Price$10.90
Change+$0.09 (+0.83%)
Volume$1.3M
Capitalization1.62B
Takeda Pharmaceutical
Price$14.84
Change-$0.29 (-1.92%)
Volume$3.16M
Capitalization43.11B
DVAX vs TAK Comparison Chart in %
Loading...
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TAK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DVAX vs. TAK commentary
Jul 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DVAX is a Buy and TAK is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 11, 2025
Stock price -- (DVAX: $10.90 vs. TAK: $14.84)
Brand notoriety: DVAX and TAK are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: DVAX: 59% vs. TAK: 147%
Market capitalization -- DVAX: $1.62B vs. TAK: $43.11B
DVAX [@Pharmaceuticals: Other] is valued at $1.62B. TAK’s [@Pharmaceuticals: Other] market capitalization is $43.11B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.81B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DVAX’s FA Score shows that 0 FA rating(s) are green whileTAK’s FA Score has 2 green FA rating(s).

  • DVAX’s FA Score: 0 green, 5 red.
  • TAK’s FA Score: 2 green, 3 red.
According to our system of comparison, TAK is a better buy in the long-term than DVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DVAX’s TA Score shows that 5 TA indicator(s) are bullish while TAK’s TA Score has 4 bullish TA indicator(s).

  • DVAX’s TA Score: 5 bullish, 4 bearish.
  • TAK’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, DVAX is a better buy in the short-term than TAK.

Price Growth

DVAX (@Pharmaceuticals: Other) experienced а +6.13% price change this week, while TAK (@Pharmaceuticals: Other) price change was -3.26% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +55.69%. For the same industry, the average monthly price growth was +84.76%, and the average quarterly price growth was +80.23%.

Reported Earning Dates

DVAX is expected to report earnings on Jul 31, 2025.

TAK is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+55.69% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TAK($43.1B) has a higher market cap than DVAX($1.62B). TAK has higher P/E ratio than DVAX: TAK (36.79) vs DVAX (31.63). TAK YTD gains are higher at: 12.085 vs. DVAX (-14.644). TAK has higher annual earnings (EBITDA): 1.01T vs. DVAX (9.67M). TAK has more cash in the bank: 317B vs. DVAX (742M). DVAX has less debt than TAK: DVAX (257M) vs TAK (4.66T). TAK has higher revenues than DVAX: TAK (4.17T) vs DVAX (232M).
DVAXTAKDVAX / TAK
Capitalization1.62B43.1B4%
EBITDA9.67M1.01T0%
Gain YTD-14.64412.085-121%
P/E Ratio31.6336.7986%
Revenue232M4.17T0%
Total Cash742M317B0%
Total Debt257M4.66T0%
FUNDAMENTALS RATINGS
DVAX vs TAK: Fundamental Ratings
DVAX
TAK
OUTLOOK RATING
1..100
1457
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
8
Undervalued
PROFIT vs RISK RATING
1..100
69100
SMR RATING
1..100
9384
PRICE GROWTH RATING
1..100
6052
P/E GROWTH RATING
1..100
9819
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TAK's Valuation (8) in the Pharmaceuticals Major industry is somewhat better than the same rating for DVAX (68) in the Biotechnology industry. This means that TAK’s stock grew somewhat faster than DVAX’s over the last 12 months.

DVAX's Profit vs Risk Rating (69) in the Biotechnology industry is in the same range as TAK (100) in the Pharmaceuticals Major industry. This means that DVAX’s stock grew similarly to TAK’s over the last 12 months.

TAK's SMR Rating (84) in the Pharmaceuticals Major industry is in the same range as DVAX (93) in the Biotechnology industry. This means that TAK’s stock grew similarly to DVAX’s over the last 12 months.

TAK's Price Growth Rating (52) in the Pharmaceuticals Major industry is in the same range as DVAX (60) in the Biotechnology industry. This means that TAK’s stock grew similarly to DVAX’s over the last 12 months.

TAK's P/E Growth Rating (19) in the Pharmaceuticals Major industry is significantly better than the same rating for DVAX (98) in the Biotechnology industry. This means that TAK’s stock grew significantly faster than DVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DVAXTAK
RSI
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
70%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
72%
Bullish Trend 1 day ago
38%
Momentum
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
60%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
43%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
72%
Bearish Trend 1 day ago
49%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
42%
Advances
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 11 days ago
43%
Declines
ODDS (%)
Bearish Trend 18 days ago
80%
Bearish Trend 3 days ago
44%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
83%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
37%
View a ticker or compare two or three
Interact to see
Advertisement
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TAK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WCPSX41.59N/A
N/A
Communication Services UltraSectorProSvc
LDFVX15.94N/A
N/A
Lord Abbett Fundamental Equity A
SCSRX19.95N/A
N/A
Allspring Common Stock R6
SIMYX12.93N/A
N/A
SEI Tax-Managed Intl Mgd Vol Y (SIMT)
JVAQX39.73N/A
N/A
JPMorgan Value Advantage R4